The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict DR Horton's revenues will grow 32.9% and EPS will grow 46.2%.
The average estimate for revenue is $1.28 billion. On the bottom line, the average EPS estimate is $0.19.
Last quarter, DR Horton tallied revenue of $1.28 billion. GAAP reported sales were 41% higher than the prior-year quarter's $906.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at $0.20. GAAP EPS of $0.20 for Q1 were 122% higher than the prior-year quarter's $0.09 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 19.6%, 260 basis points better than the prior-year quarter. Operating margin was 8.6%, 470 basis points better than the prior-year quarter. Net margin was 5.2%, 210 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $6.21 billion. The average EPS estimate is $1.04.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 586 members out of 1,139 rating the stock outperform, and 553 members rating it underperform. Among 297 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 157 give DR Horton a green thumbs-up, and 140 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on DR Horton is outperform, with an average price target of $21.23.
The rich are different than you and me: They might not notice the moneymaking stories right under our noses. In our new report, "Middle-Class Millionaire-Makers: 3 Stocks Wall Street's Too Rich to Notice," we give you three Peter Lynch-inspired buy-what-you-know stocks for the 99%. Click here for instant access to this free report.
- Add DR Horton to My Watchlist.